Publications
May 26, 2026
Oral NLRP3 inhibitor ruvonoflast provides rapid, robust and reversible inflammation reduction in people with residual inflammatory risk of ASCVD
Ray, Annual Meeting of the European Atherosclerosis Society (EAS)
These slides were originally presented at EAS 2026 (Athens, Greece) and are shared solely for scientific exchange and educational purposes. Ruvonoflast is an investigational product and is not an approved treatment.
May 26, 2026
Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
Ray, et al., Journal of the American College of Cardiology
February 21, 2026
CNS-targeted NLRP3 Inhibition by NT-0527 confers therapeutic advantage in a CAPS mouse model
Koller, et al., Journal of Neuroinflammation
January 26, 2026
Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1
Digby, et al., ACS Chemical Neuroscience
December 3, 2025
Quelling the fire within: inhibiting the NLRP3 inflammasome to treat chronic inflammation in multiple diseases
NodThera, Nature Research Custom Media
November 19, 2025
Evaluating the in vivo efficacy of NLRP3 inhibitor NT-0249 in preclinical models of chronic joint pain
Society for Neuroscience Annual Meeting | San Diego, CA
November 6, 2025
NLRP3 Inhibitor, NT-0796 Reduces MASH in Preclinical Models
Obesity Week 2025 | Atlanta, Georgia
Sep 04, 2025
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders
Harrison et al., RSC Medicinal Chemistry
Aug 12, 2025
Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inflammasome inhibitor NT-0796 in subjects with Parkinson’s disease
Clarke et al., Movement Disorders
Apr 30, 2025
The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model
Thornton et al., Obesity (Silver Spring)
Dec 02, 2024
Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?
Harrison, Journal of Medicinal Chemistry
Jul 26, 2024
The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1
Doedens et al., Biochemical Pharmacology
Apr 18, 2024
Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework
Doedens et al., ACS Pharmacology & Translational Science
Feb 09, 2024
Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796
Thornton et al., The Journal of Pharmacology and Experimental Therapeutics
Jan 22, 2024
Target Cell Activation of a Structurally Novel NLRP3 Inhibitor NT-0796 Enhances Potency
Smolak et al., Drug Discovery and Translational Medicine
Oct 24, 2023
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
Harrison et al., Journal of Medicinal Chemistry
Aug 01, 2022
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors
Harrison et al., ACS Medicinal Chemistry Letters
Dec 01, 2020
Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors
Harrison et al., Bioorganic & Medicinal Chemistry Letters
For more details, read our press release.